Literature DB >> 10482808

Increased blood-brain barrier permeability in LP-BM5 infected mice is mediated by neuroexcitatory mechanisms.

Y Kustova1, A Grinberg, A S Basile.   

Abstract

Serum protein levels in LP-BM5 infected mouse brains were investigated to gain insight into the contribution of blood-brain barrier (BBB) patency to the pathogenesis of retroviral encephalopathy. Evans blue uptake by the forebrain and cerebellum was significantly increased between 8-12 weeks post inoculation. Immunohistochemistry revealed foci of albumin, transferrin, alpha(2)-macroglobulin and IgG transudation around blood vessels particularly in the cerebral cortex and cerebellar vermis. These leaks were often associated with astrocytosis and apoptotic cells. Unlike the other serum proteins, IgG immunoreactivity extended from the circumventricular organs and disseminated throughout the brain parenchyma, accumulating on the plasma membranes of hippocampal and cortical neurons. Consistent with the chronic elevation of free glutamate levels in LP-BM5 infected mice, the increase in Evans blue uptake into the forebrain was completely reversed following dizocilpine administration. Thus, the chronic increase in free glutamate levels in LP-BM5 infected mouse brain contributes to BBB disruption. Furthermore, the CNS accumulation of serum proteins, particularly IgG, observed in these mice may increase osmotic load, impair neuronal function, and cause white matter pallor. Administration of NMDA receptor antagonists may prove useful in managing BBB permeability in those neuropathologies, such as HIV-associated dementia/cognitive/motor complex, having a glutamatergic component.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482808     DOI: 10.1016/s0006-8993(99)01734-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor.

Authors:  E Koustova; Y Sei; L Fossom; M L Wei; P N Usherwood; N B Keele; M A Rogawski; A S Basile
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Blood-brain barrier dysfunction and recovery.

Authors:  A G de Boer; P J Gaillard
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

Review 3.  T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.

Authors:  Muhammad Mukhtar; Edward Acheampong; Zahida Parveen; Roger J Pomerantz
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 4.  Rodent model systems for studies of HIV-1 associated dementia.

Authors:  Y Persidsky; R Potula; J Haorah
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

Review 5.  Astrocyte-endothelial interactions and blood-brain barrier permeability.

Authors:  N Joan Abbott
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

6.  Pcbs and tight junction expression.

Authors:  Sung Yong Eum; Ibolya E András; Pierre-Olivier Couraud; Bernhard Hennig; Michal Toborek
Journal:  Environ Toxicol Pharmacol       Date:  2008-03       Impact factor: 4.860

7.  Morphine increases hippocampal viral load and suppresses frontal lobe CCL5 expression in the LP-BM5 AIDS model.

Authors:  Virginia D McLane; Ling Cao; Colin L Willis
Journal:  J Neuroimmunol       Date:  2014-02-28       Impact factor: 3.478

8.  Aberrant immune responses in a mouse with behavioral disorders.

Authors:  Yong Heo; Yubin Zhang; Donghong Gao; Veronica M Miller; David A Lawrence
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

9.  Effects of Morphine on Gp120-induced Neuroinflammation Under Immunocompetent Vs. Immunodeficient Conditions.

Authors:  Dalton Canonico; Sadie Casale; Tristan Look; Ling Cao
Journal:  J Neuroimmune Pharmacol       Date:  2022-01-21       Impact factor: 7.285

10.  Nitrosative damage during retrovirus infection-induced neuropathic pain.

Authors:  Priyanka Chauhan; Wen S Sheng; Shuxian Hu; Sujata Prasad; James R Lokensgard
Journal:  J Neuroinflammation       Date:  2018-03-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.